drugset / Trial / NCT07316166

Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine

NCT07316166

Phase 4 Recruiting 120 enrolled Rhode Island Hospital
RandomizedParallel-groupTriple-blindSupportive care

Summary

The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.

Timeline

Start
2026-01-20
Primary completion
2027-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ug/kg Other
Background Ropivacaine Other / unclassified 0.25 % Other
Background Ropivacaine Other / unclassified 30 ml Other

Indications

No indication recorded.